Preclinical studies of the combination of dual PI3K/Akt/mTOR inhibitors with radiotherapy to overcome radioresistant prostate cancer

被引：0
|
作者：
Chang, Lei [1 ,2 ,3 ]
Graham, Peter H. [1 ,2 ,3 ]
Hao, Jingli [1 ,2 ,3 ]
Jie Ni [1 ,2 ,3 ]
Bucci, Joseph [1 ,2 ,3 ]
Cozzi, Paul J. [1 ,2 ,3 ,4 ]
Kearsley, John H. [1 ,2 ,3 ]
Li, Yong [1 ,2 ,3 ]
机构：
[1] St George Hosp, Canc Care Ctr, Sydney, NSW, Australia
[2] St George Hosp, Prostate Canc Inst, Sydney, NSW, Australia
[3] Univ New S Wales, Fac Med, St George & Sutherland Clin Sch, Kensington, NSW 2033, Australia
[4] St George Hosp, Dept Surg, Sydney, NSW, Australia
来源：
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE | 2014年 / 34卷
关键词：
Prostate cancer; radiation therapy; radioresistance; PI3K/Akt/mTOR inhibitor; cancer stem cell;
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
281
引用
收藏
页码：S50 / S50
页数：1
相关论文
共 50 条
  • [1] Activation of PI3K/Akt/mTOR Pathway and Dual Inhibitors of PI3K and mTOR in Endometrial Cancer
    Chen, Jiezhong
    Zhao, Kong-Nan
    Li, Rui
    Shao, Renfu
    Chen, Chen
    CURRENT MEDICINAL CHEMISTRY, 2014, 21 (26) : 3070 - 3080
  • [2] Preclinical studies of the PI3K/mTOR dual inhibitors in endometrial cancer cell lines
    Yuan, Jing
    Garza, Scott J.
    Cao, Joan
    Fisher, Timothy S.
    Lee, Nathan V.
    Eisele, Koleen
    Pasis, Angela
    Hook, Kenneth
    Christensen, James G.
    Kan, Julie L.
    CANCER RESEARCH, 2012, 72
  • [3] Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
    Roudsari, Nazanin Momeni
    Lashgari, Naser-Aldin
    Momtaz, Saeideh
    Abaft, Shaghayegh
    Jamali, Fatemeh
    Safaiepour, Pardis
    Narimisa, Kiyana
    Jackson, Gloria
    Bishayee, Anusha
    Rezaei, Nima
    Abdolghaffari, Amir Hossein
    Bishayee, Anupam
    PHARMACEUTICS, 2021, 13 (08)
  • [4] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, (04) : 342 - 354
  • [5] PI3K/Akt/mTOR inhibitors in breast cancer
    Lee, Joycelyn J. X.
    Loh, Kiley
    Yap, Yoon-Sim
    CANCER BIOLOGY & MEDICINE, 2015, 12 (04) : 342 - 354
  • [6] PI3K/AKT/mTOR Inhibitors In Ovarian Cancer
    Mazzoletti, M.
    Broggini, M.
    CURRENT MEDICINAL CHEMISTRY, 2010, 17 (36) : 4433 - 4447
  • [7] PI3K/Akt/mTOR inhibitors in breast cancer
    Joycelyn JX Lee
    Kiley Loh
    Yoon-Sim Yap
    Cancer Biology & Medicine, 2015, 12 (04) : 342 - 354
  • [8] The PI3K/AKT/MTOR signaling pathway: The role of PI3K and AKT inhibitors in breast cancer
    Huemer F.
    Bartsch R.
    Gnant M.
    Current Breast Cancer Reports, 2014, 6 (2) : 59 - 70
  • [9] PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
    Alzahrani, Ali S.
    SEMINARS IN CANCER BIOLOGY, 2019, 59 : 125 - 132
  • [10] PI3K/Akt/mTOR dual inhibitors have an advantage over single inhibitors in overcoming prostate cancer radioresistance.
    Chang, Lei
    Graham, Peter
    Hao, Jingli
    Ni, Jie
    Bucci, Joseph
    Cozzi, Paul
    Kearseley, John
    Li, Yong
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
12345